Page 1,528«..1020..1,5271,5281,5291,530..1,5401,550..»

Eli Lilly Unveils $90M Expanded Biotechnology Center in San Diego – Times of San Diego

Posted: June 24, 2017 at 1:45 pm

Share This Article:

Pharmaceutical giant Eli Lilly announced the completion of a $90 million expansion of its San Diego biotechnology center, which is now more than double its previous size with the addition of 180,000 square feet of work space.

The facility, on Campus Point Drive near UC San Diego, also includes a new high-tech laboratory and room for what the Indianapolis-based company calls a Life Science Studio.

Eli Lilly moved into San Diego in 2004 with the acquisition of Applied Molecular Evolution Inc., and built its Biotechnology Center in 2009.

Being in the San Diego area for the last 13 years has been a game changer for us, specifically in the arena of discovering medicines for hard-to- treat autoimmune conditions, said Thomas F. Bumol, Lillys senior vice president of biotechnology and immunology research.

Company officials said they hope the new facility will allow closer collaboration among researchers. The center originally focused on immunology, but in the larger facility, scientists will also work on diabetes, oncology, neurodegeneration and pain reduction.

Investing in drug discovery and development is critical to maintaining an ecosystem that encourages and promotes innovation, said Jan Lundberg, executive vice president for science and technology and president of Lilly Research Laboratories.

Our expansion in San Diego is a prime example of investing in a research success story, Lundberg said. Expanding our presence in San Diego will not only help us discover and deliver innovative medicines faster, but will also help us achieve our goal of launching 20 new medicines in 10 years.

According to Eli Lilly, the Life Science Studio will allow researchers across the globe to remotely design, synthesize and screen molecules in an unprecedented manner, expanding the ability of scientists to test new ideas, reduce costs and minimize environmental impacts.

City News Service

Eli Lilly Unveils $90M Expanded Biotechnology Center in San Diego was last modified: June 24th, 2017 by Debbie L. Sklar

>> Subscribe to Times of San Diegos free daily email newsletter! Click here

Excerpt from:
Eli Lilly Unveils $90M Expanded Biotechnology Center in San Diego - Times of San Diego

Posted in Biotechnology | Comments Off on Eli Lilly Unveils $90M Expanded Biotechnology Center in San Diego – Times of San Diego

Roche’s lampalizumab halts geographic atrophy – European Biotechnology

Posted: June 24, 2017 at 1:45 pm

A publication in Science Translational Medicine shows that Roche has a rising star in the 15 million patient market of age-related macular degeneration (AMD). In a Phase II trail US and German researchers showed efficacy in geographic atrophy, an advanced stage of AMD, which has currently no treatment.

One week prior to the publication, Roche announced it has intitiated two Phase III trails (CHROMA and SPECTRI) enroling 936 patients with the advanced form of AMD that affects 5 million AMD patients and has currently no cure. Primary endpoint is slowing for disease progression at 12 months, secondary endpoint is visual acuity at 24 months. However, rumors say the FDA could accelerate patient access through granting breakthrough status to the treatment.

In a multi-center, randomized, 18 month Phase study that recruited 129 AMD patients ( MAHALO), lead author Brian Yaspan observed a 20% reduction in lesion area progression in patients receiving Roche/Genentechs antibody drug candidate lampalizumab at acceptable safety profile. Lampalizumab zeroes in on complement D, part of the innate immune defenses alternative complement pathway

Genome analysis of participants identified a patient subgroup with complement D variants who showed a 44% reduction in geographic atrophy area progression. The authors say targeting the alternative complement pathway has potential to be a viable treatment option for patients with secondary geographic atrophy.

Go here to see the original:
Roche's lampalizumab halts geographic atrophy - European Biotechnology

Posted in Biotechnology | Comments Off on Roche’s lampalizumab halts geographic atrophy – European Biotechnology

Play the iShares Nasdaq Biotechnology Index (ETF)’s (IBB) Popularity for Free – Investorplace.com

Posted: June 24, 2017 at 1:45 pm

Wall Street is going gaga over the healthcare and biotech sector. The iShares Nasdaq Biotechnology Index (ETF) (NASDAQ:IBB) rallied 9% in four days. TheSPDR S&P Biotech (ETF) (NYSEARCA:XBI) rallied even more.

These are impressive moves that deserve respect. But I cannot chase it if I am not already on board the trade. Or I will end up buying someone elses profits. Wall Street loves to trade memes these days. A few weeks ago the IBB was dead money, now they cant have enough of it.

The hoopla centers around expectations from the new healthcare bill. I think we are giving it too much credit. We dont know if it will pass and even if it does, we dont know its full effects. But I am willing to bet that it wont be better to the sector than Obamacare was. This new bill is likely to be less, and therefore we could have a disappointment period coming.

Click to Enlarge Before you label me a perma-bear, I was a fan of the IBB a few weeks ago. Instead of chasing the momentum after it happens, a bit a good homework delivered great results. Case in point is this massive win from a bullish trade I shared on May 23 which yielded easy profits and out of thin air.

Now that everyone and their sister is chasing this rally in the IBB, I am ready to try and short it. Before you send out the posse to arrest me for daring to short the hot topic du jour, my trade is not against the sector, but rather is my bet against the short-term price action. I like to go long IBB on weakness but here I see the potential for a dip.

A lot of the enthusiasm is tied to politicians doing the right thing, and I am not so sure they will deliver. Even if they do, its probably going to take longer and be less than we expect. Eventually, traders will get antsy and lose interest and the IBB bids will abate, thereby creating a small vacuum below the current steep wedge. Therein lies the opportunity.

The Bearish Bet: Buy the IBB Aug $315/310 debit put spread for $1.50 or better per contract. If price falls through my spread in the next 56 days, I could triple my money. The faster and sooner the fall, the better otherwise time is my enemy.

To mitigate my out-of-pocket risk, I will leverage the value in the IBB ETF. I will sell longer dated puts to finance my bearish bet.

The Bank: Sell IBB Dec $270 puts and collect $5 per contract. This is a bullish trade which has a 90% theoretical chance of success. But if the IBB falls through my short put, then I will own the shares and could accrue losses below $265. But if Wall Street is correct about the political exuberance in the biotech sector, then I really have nothing to worry about. For a smaller risk profile, I could use a credit put spread instead.

Selling options is risky, so I never risk more than I am willing or able to lose.

Learn how to generate income from options here. Nicolas Chahine is the managing director of SellSpreads.com. As of this writing, he did not hold a position in any of the aforementioned securities. You can follow him on Twitter at @racernicand stocktwits at@racernic.

More:
Play the iShares Nasdaq Biotechnology Index (ETF)'s (IBB) Popularity for Free - Investorplace.com

Posted in Biotechnology | Comments Off on Play the iShares Nasdaq Biotechnology Index (ETF)’s (IBB) Popularity for Free – Investorplace.com

Stem cells: the future of medicine – Medical Xpress

Posted: June 24, 2017 at 1:44 pm

June 23, 2017

Imagine being able to take cells from your skin, transform them into other types of cells, such as lung, brain, heart or muscle cells, and use those to cure your ailments, from diabetes to heart disease or macular degeneration. To realise this, however, challenges still remain, Professor Janet Rossant, a pioneer in the field, says.

All across the world, scientists have begun clinical trials to try and do just that, by making use of the incredible power and versatility of stem cells, which are special cells that can make endless copies of themselves and transform into every other type of cell.

While human embryos contain embryonic stem cells, which help them to develop, the use of those cells has been controversial. The scientists are using induced pluripotent stem cells instead, which are other cells that have been reprogrammed to behave like stem cells.

"There are still significant challenges that we need to overcome, but in the long run we might even be able to create organs from stem cells taken from patients. That would enable rejection-free transplants," said Professor Janet Rossant, a pioneer in the field.

The mouse that changed everything

A speaker at the recent Commonwealth Science Conference 2017 held in Singapore and organised by Britain's Royal Society and Singapore's National Research Foundation, Prof Rossant gave an overview of stem cells' origins, history, uses and potential.

Now a senior scientist at The Hospital for Sick Children (also known as Sick Kids) in Toronto, Canada, after a decade as its chief of research, she was the first scientist to demonstrate the full power of stem cells in mice.

In the early 1990s, scientists believed that stem cells could only become certain types of cells and carry out limited functions. Based on her own research and that of others, however, Prof Rossant believed that they were capable of far more.

Working with other scientists, she created an entire mouse out of stem cells in 1992, upending the conventional wisdom. "We went on to create many baby mice that were completely normal, and completely derived from stem cells grown in a petri dish," she said.

"That was an amazing experiment, and it was instrumental in making people believe that human embryonic stem cells could have the full potential to make every cell type in the body," she added.

When scientists learned how to remove stem cells from human embryos in 1998, however, controversy ensued. Many lobbied against the cells' use in medical research and treatment due to the moral implications of destroying even unwanted embryos to gain the cells.

In Canada, Prof Rossant chaired the working group of the Canadian Institutes of Health Research on Stem Cell Research, establishing guidelines for the field. These guidelines helped to keep the field alive in Canada, and were influential well beyond the country's borders.

In 2006, Japanese researchers succeeded in taking skin cells from adult mice and reprogramming them to behave like embryonic stem cells. These revolutionary, induced pluripotent stem (IPS) cells allowed scientists to sidestep the ongoing controversy.

The challenges in the way

While stem cells have been used for medical treatment in some cases bone marrow transplants, for example, are a form of stem cell therapy there are several challenges that need to be overcome before they can be used more widely to treat diseases and injuries.

"We need to get better at turning stem cells into the fully mature cells that you need for therapy. That's going to take more work. Another issue is that of scale-up. If you're going to treat a patient, you need to be able to grow millions of cells," said Prof Rossant.

She added: "Safety is another concern. One of the most exciting things about pluripotent stem cells is that they can divide indefinitely in the culture dish. But that's also one of the most scary things about them, because that's also how cancer works.

"Furthermore, because we need to genetically manipulate cells to get IPS cells, it's very hard to know whether we've got completely normal cells at the end of the day. These are all issues that need to be resolved."

She noted that some scientists are working on making "failsafe" IPS cells, which have a built-in self-destruct option if they become dangerous. "Bringing stem cells into regenerative medicine is going to require interdisciplinary, international collaboration," she said.

In the meantime, stem cells have been a boon to medical research, as scientists can use them to create an endless supply of different cells to study diseases and injuries, and test drugs. "That's the biggest use of IPS cells right now," Prof Rossant said.

Sick kids and how to help them

At SickKids, which is Canada's largest paediatric research hospital, she has been using stem cells to study cystic fibrosis, a frequently fatal genetic disorder that causes mucus to build up and clog some organs such as the lungs. It affects primarily children and young adults.

SickKids discovered the CFTR gene that, when mutated, causes the disease. It was also the first to produce mature lung cells, from stem cells, that can be used to study the disease and test drugs against it.

Even better, Prof Rossant and her team were able to turn skin cells from cystic fibrosis patients into IPS cells and then into lung cells with the genetic mutation specific to each of them. This is critical to personalising treatment for each patient.

"Drugs for cystic fibrosis are extraordinarily expensive, and patients can have the same mutation and yet respond differently to the same drug," Prof Rossant explained. "With our work, we can make sure that each patient gets the right drug at the right time."

In 1998, Prof Rossant also discovered a new type of stem cell in mice, now called the trophoblast stem cell. These surround an embryo and attach it to the uterine wall, eventually becoming the placenta. She is using such cells to study placenta defects and pregnancy problems.

By using IPS cells to create heart cells and other cells, pharmaceutical companies can also test their new drugs' effectiveness and uncover potential side effects, as well as develop personalised medicines.

"There are still huge amounts of opportunities in pluripotent stem cells," said Prof Rossant, who has won numerous awards for her research, including the Companion of the Order of Canada and the 2016 Friesen International Prize in Health Research.

She is also president and scientific director of the Toronto-based Gairdner Foundation, which recognises outstanding biomedical research worldwide, and a professor at the University of Toronto's molecular genetics, obstetrics and gynaecology departments.

"Meetings like the Commonwealth Science Conference are a fantastic opportunity for scientists to come together, learn about each other's work and establish new relationships, which will help to push science forward, including in stem cell research," she said.

She noted: "The world of science is becoming increasingly interdisciplinary, so this kind of meeting of minds across nations, cultures and scientific fields is really the way of the future."

Explore further: Cardiac stem cells from heart disease patients may be harmful

Discovered more than two decades ago, the hormone leptin has been widely hailed as the key regulator of leanness. Yet, the pivotal experiments that probe the function of this protein and unravel the precise mechanism of its ...

New research overturns long-held views on a basic messaging system within living cells. Key cellular communication machinery is more regionally constrained within the cell than previously thought. The findings suggest new ...

Scientists used human pluripotent stem cells to generate human embryonic colons in a laboratory that function much like natural human tissues when transplanted into mice, according to research published June 22 in Cell Stem ...

The leading cause of acute gastroenteritis linked to eating raw seafood disarms a key host defense system in a novel way: It paralyzes a cell's skeleton, or cytoskeleton.

It's a tiny marine invertebrate, no more than 3 millimeters in size. But closely related to humans, Botryllus schlosseri might hold the key to new treatments for cancer and a host of vascular diseases.

Paracetamol is popular for relieving pain. But if you are pregnant, you should think twice before popping these pills according to the researchers in a new study. In an animal model, Paracetamol, which is the pain-relieving ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

See the article here:
Stem cells: the future of medicine - Medical Xpress

Posted in Cell Medicine | Comments Off on Stem cells: the future of medicine – Medical Xpress

‘Lifting the cloud’ of diabetes with a special dog – Burnett County Sentinel (subscription)

Posted: June 24, 2017 at 1:43 pm

Since her diagnosis of Type 1 diabetes in 2009, Madyi Stangl has felt that the disease has placed a cloud on her life limiting her ability to travel and live life.

But that cloud has lifted, thanks to a special golden retriever named Willy.

Willy is a diabetes assistance dog that was given to Stangl by Can Do Canines, a New Hope, Minn., based non-profit organization that trains dogs to help people who live with diabetes, autism, seizures, hearing loss and mobility issues.

Madyi and Willy graduated in a class of 14 on June 10.

Willy can detect changes in Stangls blood sugar levels by scent. He alerts Madyi to high or low blood sugar levels by touching her with his paw. If she doesnt respond, he will whine or whimper and eventually do whatever he needs to do to get her attention. He is trained to bring glucose tablets or even a cell phone to Stangl.

Recently, Stangl had a scary low of 34 during the night. When she failed to respond to Willys touches, he laid over her body until she woke up. She then checked her blood sugar levels and ate food to bring her levels back up to normal, saving her life.

Can Do Canines has produced nearly 600 teams of dogs and their human companions since opening in 1989, according to Client Services Coordinator Sarah Schaff.

The organization can give away the dogs, which are sold by other organizations for $20,000 or more, because of volunteers and many donors, Schaff says.

Funding comes from donations from individuals, companies and grants. Schaff reports that the organization does not receive any state or federal funds, relying solely on donations, fundraisers and bequests.

Puppies are bred in a cooperative program with other certified service dog organizations, raised by volunteers and many receive their initial training in six Minnesota and two Wisconsin prisons.

Schaff notes that the prison environment is good for the dogs as well as the inmates.

It gives dogs a 24/7 taste of what life will be like when they are working, she says, adding that there are many studies pointing to the therapeutic benefits for the inmate handlers as well.

The organization has a screening process to find suitable candidates to match with dogs that are in the system or are in training.

It takes two years to raise and train a dog to be an assistance animal, Schaff says.

Madyi lives ub Minneapolis and works as the Operations Lead for the University of Minnesota Physicians, and Willy accompanies her to work as well. He even alerted a diabetic co-worker to a low blood sugar level.

Stangl grew up with dogs and reports that having Willy around is like having a big security blanket that I carry with me all the time. She is now more confident as well.

Even though Im going to continue on as this girl with this physical reminder of my disability, Im a little prouder because Im able to shed light on diabetes. Diabetes is an invisible illness, but it is something that needs to be seen because its not something to be taken lightly, she says.

Even though Willy is a beautiful and friendly dog, Stangl asks that people should refrain from touching him or any other assistance dog without permission of the owner.

When we are out in public and Willy is wearing his vest, its important not to make eye contact or distract him, Stangl says. He is working for me, and if he gets distracted, he stops working and that could be dangerous.

Schaff says that Can Do Canines is in need of volunteers to raise and train labrador, collie and poodle puppies for two years and return them to the company for further training.

See original here:
'Lifting the cloud' of diabetes with a special dog - Burnett County Sentinel (subscription)

Posted in Diabetes | Comments Off on ‘Lifting the cloud’ of diabetes with a special dog – Burnett County Sentinel (subscription)

BD fun run to benefit juvenile diabetes research | Local | kearneyhub … – Kearney Hub

Posted: June 24, 2017 at 1:43 pm

LOOMIS Becton Dickinson wants to help cure or find a better way to treat diabetes, so the medical equipment manufacturer supports the Juvenile Diabetes Research Foundation.

To do so, BD is sponsoring a 2K Color Fun Run July 1 in Loomis. It will begin at Loomis High School and will end at the communitys water park.

Usually, we sponsor an event inside the plant, but we decided to do something different this year, said Holdrege BD employee and event leader Sheri Freeland.

Donations will benefit the Juvenile Diabetes Research Foundation Lincoln and Greater Nebraska Chapter to create a world without type 1 diabetes, an autoimmune disease in which a persons pancreas stops producing insulin. Insulin is a hormone people need to get energy from food.

The disease can suddenly strike both children and adults. Type 1 diabetes is unrelated to diet or lifestyle. People with type 1 diabetes must regularly monitor their blood-sugar levels, inject or continually infuse insulin through a pump, and carefully regulate insulin doses with eating and activity 24 hours a day.

The juvenile diabetes foundation funds research to deliver new treatments and therapies that make day-to-day life with diabetes easier, safer and healthier until it can prevent and one day cure the disease.

After hearing a speech from 13-year-old Riley Kinnan, who was diagnosed with diabetes at the age of 7, Freeland knew leading this event was something she wanted to do.

(Her speech) was interesting and motivating. Since Ive worked (at BD) for 36 years, I felt like I should do something, and I knew this was a great way to help out, said Freeland.

Riley, an eighth-grader to be from Lincoln, is an ambassador for the juvenile diabetes foundation. She is very passionate about helping younger children, especially those who are also dealing with the challenges of a diabetes diagnosis.

In the past, BD has sponsored diabetes foundation events such as chili cookoffs, salsa-making contests, hamburger feeds and silent auctions. It has sponsored the juvenile diabetes foundation for six or seven years.

There are 30 people signed up for the Color Run, and Freeland said she has already sold 80 T-shirts for the occasion. All proceeds are going to the juvenile diabetes foundation, and BD is matching the money raised.

Freeland said she is grateful for the number of people who have signed up so far to participate.

We werent sure if we would have enough people or money to put this event together, but we ended up having many volunteers and people in the community willing to help out.

With continued publicity for the event, Freeland hopes to help those suffering with diabetes.

Its a scary disease, and it can affect so young. There are kids that are 2 or even younger that have it, and its terrifying to think about how many shots to have daily and watching what you eat constantly. Its not like you can take a pill and make it go away. For kids, it just sucks, Freeland said.

Read more from the original source:
BD fun run to benefit juvenile diabetes research | Local | kearneyhub ... - Kearney Hub

Posted in Diabetes | Comments Off on BD fun run to benefit juvenile diabetes research | Local | kearneyhub … – Kearney Hub

Bioengineers create more durable, versatile wearable for diabetes … – Phys.Org

Posted: June 24, 2017 at 1:43 pm

June 23, 2017 Researchers at the University of Texas at Dallas have developed a wearable diagnostic biosensor that can detect three interconnected, diabetes-related compounds -- cortisol, glucose and interleukin-6 -- in perspired sweat for up to a week without loss of signal integrity. The team envisions that their wearable devices will contain a small transceiver to send data to an application installed on a cellphone. Credit: University of Texas at Dallas

Researchers at The University of Texas at Dallas are getting more out of the sweat they've put into their work on a wearable diagnostic tool that measures three diabetes-related compounds in microscopic amounts of perspiration.

"Type 2 diabetes affects so many people. If you have to manage and regulate this chronic problem, these markers are the levers that will help you do that," said Dr. Shalini Prasad, professor of bioengineering in the Erik Jonsson School of Engineering and Computer Science. "We believe we've created the first diagnostic wearable that can monitor these compounds for up to a week, which goes beyond the type of single use monitors that are on the market today."

In a study published recently in Scientific Reports, Prasad and lead author Dr. Rujute Munje, a recent bioengineering PhD graduate, describe their wearable diagnostic biosensor that can detect three interconnected compounds - cortisol, glucose and interleukin-6 - in perspired sweat for up to a week without loss of signal integrity.

"If a person has chronic stress, their cortisol levels increase, and their resulting insulin resistance will gradually drive their glucose levels out of the normal range," said Prasad, Cecil H. and Ida Green Professor in Systems Biology Science. "At that point, one could become pre-diabetic, which can progress to type 2 diabetes, and so on. If that happens, your body is under a state of inflammation, and this inflammatory marker, interleukin-6, will indicate that your organs are starting to be affected."

Last October, Prasad and her research team confirmed they could measure glucose and cortisol in sweat. Several significant advances since then have allowed them to create a more practical, versatile tool.

"We wanted to make a product more useful than something disposable after a single use," Prasad said. "It also has to require only your ambient sweat, not a huge amount. And it's not enough to detect just one thing. Measuring multiple molecules in a combinatorial manner and tracking them over time allows us to tell a story about your health."

One factor that facilitated their device's progress was the use of room temperature ionic liquid (RTIL), a gel that serves to stabilize the microenvironment at the skin-cell surface so that a week's worth of hourly readings can be taken without the performance degrading over time.

"This greatly influences the cost model for the deviceyou're buying four monitors per month instead of 30; you're looking at a year's supply of only about 50," Prasad said. "The RTIL also allows the detector to interface well with different skin typesthe texture and quality of pediatric skin versus geriatric skin have created difficulties in prior models. The RTIL's ionic characteristics make it somewhat like applying moisturizer to skin."

Prasad's team also determined that their biomarker measurements are reliable with a tiny amount of sweatjust 1 to 3 microliters, much less than the 25 to 50 previously believed necessary.

"We actually spent three years producing that evidence," Prasad said. "At those low volumes, the biomolecules expressed are meaningful. We can do these three measurements in a continuous manner with that little sweat."

Prasad envisions that her wearable devices will contain a small transceiver to send data to an application installed on a cellphone.

"With the app we're creating, you'll simply push a button to request information from the device," Prasad said. "If you measure levels every hour on the hour for a full week, that provides 168 hours' worth of data on your health as it changes."

That frequency of measurement could produce an unprecedented picture of how the body responds to dietary decisions, lifestyle activities and treatment.

"People can take more control and improve their own self-care," Prasad said. "A user could learn which unhealthy decisions are more forgiven by their body than others."

Prasad has emphasized "frugal innovation" throughout the development process, making sure the end product is accessible for as many people as possible.

"We've designed this product so that it can be manufactured using standard coating techniques. We made sure we used processes that will allow for mass production without adding cost," Prasad said. "Our cost of manufacturing will be comparable to what it currently takes to make single-use glucose test stripsas little as 10 to 15 cents. It needs to reach people beyond America and Europeand even within first-world nations, we see the link between diabetes and wealth. It can't simply be a small percentage of people who can afford this."

Prasad was motivated to address this specific problem in part by her own story.

"South Asians, like myself, are typically prone to diabetes and to cardiovascular disease," Prasad said. "If I can monitor on a day-to-day basis how my body is responding to intake, and as I age, if I can adjust my lifestyle to keep those readings where they need to be, then I can delay getting a disease, if not prevent it entirely."

For Prasad, the latest work is a fulfilling leap forward in what has already been a five-year process.

"We've been solving this problem since 2012, in three phases," Prasad said. "The initial concept for a system level integration of these sensors was done in collaboration with EnLiSense LLC, a startup focused on enabling lifestyle based sensors and devices. In the market, there's nothing that is a slap-on wearable that uses perspired sweat for diagnostics. And I think we are the closest. If we find the right partner, then within a 12-month window, we hope to license our technology and have our first products in the market."

Explore further: Bioengineers create sweat-based sensor to monitor glucose

More information: Rujuta D. Munje et al, A new paradigm in sweat based wearable diagnostics biosensors using Room Temperature Ionic Liquids (RTILs), Scientific Reports (2017). DOI: 10.1038/s41598-017-02133-0

Google said Friday it would stop scanning the contents of Gmail users' inboxes for ad targeting, moving to end a practice that has fueled privacy concerns since the free email service was launched.

Like driving a car despite a glowing check-engine light, large buildings often chug along without maintenance being performed on the building controls designed to keep them running smoothly.

Microphones, from those in smartphones to hearing aids, are built specifically to hear the human voicehumans can't hear at levels higher than 20 kHz, and microphones max out at around 24 kHz, meaning that microphones only ...

Researchers at The University of Texas at Dallas are getting more out of the sweat they've put into their work on a wearable diagnostic tool that measures three diabetes-related compounds in microscopic amounts of perspiration.

Researchers at the College of Engineering at Carnegie Mellon University have developed a novel design approach for exoskeletons and prosthetic limbs that incorporates direct feedback from the human body. The findings were ...

In a proof-of-concept study, North Carolina State University engineers have designed a flexible thermoelectric energy harvester that has the potential to rival the effectiveness of existing power wearable electronic devices ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

View post:
Bioengineers create more durable, versatile wearable for diabetes ... - Phys.Org

Posted in Diabetes | Comments Off on Bioengineers create more durable, versatile wearable for diabetes … – Phys.Org

Tallahassee twin toddlers learn to live with Type 1 diabetes – WTXL ABC 27

Posted: June 24, 2017 at 1:43 pm

Video Gallery - WTXL Video Template

TALLAHASSEE, Fla. (WTXL)- More than 1 million Americans are living with Type 1 diabetes (T1D), an autoimmune disease where the pancreas stops making insulin.

One out of every 400 children has T1D, and for one Tallahassee family, a pair of twins were both diagnosed before the age of 2.

"It can happen to anyone. We don't have it in our families," said Rebeka Joseph, the mother of Eva and Leah Joseph."This was a strike of lightning that hit us. Twice."

Leah was diagnosed when she was just 10 months old. Her parents thought she had the flu, but her blood sugar level was dangerously high.

"My baby was 10 months old, and she had diabetes," Rebekah said. "My life changed forever in that moment."

Just nine months later, Eva was diagnosed with T1D. Rebekah was able to detect it, thanks to the medical team at Tallahassee Memorial.

"As they grow up, there will be physicians here who can continue to take care of them," said Dr. Larry Deeb, a pediatric endocrinologistat TMH. "There will be the Diabetes Center that can continue to offer support at every stage of life."

"We're there to continue training and making sure that they make the transition -- being able to learn some of the care things themselves, so that they can take care of their bodies as they grow and develop," saidKatherine Owen, a certified diabetes educator at TMH.

TMH provided the girls with devices that monitor and administer insulin throughout the day.

"It's an hourly -- almost minute-to-minute disease," Rebekah said.

As the girls grow up, the family wants to make sure their teachers know how to handle issue with diabetes. TMH trained the staff at Good Samaritan Academy to do just that.

"The girls are able to develop as little people that can play with other kids," Rebekah said. "I want them to realize how normal they are. There's really no difference."

That's what Belinda Rodebaugh hopes for, too. She was diagnosed when she was 5 years old.

"It is part of your life, and it never goes away. However, it will respond to things that you do," Rodebaugh said."So, the more you research what you eat and what you don't is a really good thing."

The twins will celebrate their second birthday in September. The family says the support they've received gives them confidence to manage any challenge that comes their way.

More:
Tallahassee twin toddlers learn to live with Type 1 diabetes - WTXL ABC 27

Posted in Diabetes | Comments Off on Tallahassee twin toddlers learn to live with Type 1 diabetes – WTXL ABC 27

Dr. Ralph Defronzo Part 3, Diabetes Medications – Diabetes In Control

Posted: June 24, 2017 at 1:43 pm

Dr. Ralph Defronzo talks with Diabetes in Control Publisher Steve Freed during the ADA 77th Scientific Session in San Diego about SGLT-2, GLP-1, and the drugs he recommends despite standard practice.

Dr. Ralph Defronzo, MD is Professor of Medicine and Chief of the Diabetes Division at the University of Texas Health Diabetes Center in San Antonia, Texas. Dr. Defronzo is also Deputy Director of the Texas Diabetes Institute.

Transcript of this video segment:

Steve Freed:You were one of the first to use triple therapy. Certainly a more aggressive attitude. Now we have drugs that actually prevent or reduce your risk for death. Now were coming out, were finding out the SGLT-2s may cause amputation of your toes. It may cause other issues. I dont think theres a drug on the planet that doesnt have side effects. But were not going to die from the loss of a toe. What are your thoughts even when it comes to SGLT-2s? I know theyre fairly expensive right now. Competition hopefully will reduce that. What are your thoughts about the SGLT-2 drugs and the GLP-1s?

Dr. Defronzo:Let me just back up before I talk about this amputation issue, because its going to be very controversial. To me, Ive always been a strong believer that you need to understand what causes type 2 diabetes. NIH spends millions and millions of dollars to help us try to define what causes the disease. If you know what causes the disease, you ought to use medications to reverse the problem. Sulfonylureas clearly dont do that. In my opinion, these drugs, other than cost, really should not be being used in our diabetic patients. We have much better armor material. So if I had to list the drugs, and this may be a little bit different from what other people tell you. I would put a tie between GLP-1 receptor agonist and pioglitazone. And very close to those two, I would put SGLT-2 inhibitor. Id put Metformin as a good drug but lower down. Those are my four good drugs. Then way down, Id put DPP-4 inhibitors and I just dont use sulfonylurea drugs. I dont believe that theres any need for these drugs. Youd have to be very hard pressed that people could not afford any other drug before Im going to resort to using sulfonylurea drugs. Weve done a very large study with triple therapy. Its now into its 5th year. We use a combination of pioglitazone, a GLP-1 receptor agonist, and Metformin. Because when we started these studies, SGLT-2 inhibitors were not around. I can tell you now, the results are phenomenal. These people have three years later normal beta-cell function. They have a 60% improvement in insulin sensitivity. They lose weight. Theres minimal hypoglycemia. We just published a very large study inDiabetes Care, its called the Qatar Study, where theyre going to play the World Cup. We took people who had failed completely on Metformin and sulfonylurea. Their A1C was 10.1. They had ten and a half duration of this disease. We added a GLP-1 receptor agonist plus pioglitazone. A year and a half later, they have an A1C of 6. So, the beta cells, Id rather say, theyre not dead, theyre hibernating. People dont recognize that the TZDs have a huge effect on the beta cell. GLP-1 receptor agonists have a huge effect on the beta cell. And then pioglitazone also has a good insulin sensitizing effect. If I had to do this study over again, I actually would replace the Metformin with the SGLT-2 inhibitor. But these are all good drugs and docs need to learn how to mix and match them. Then they also need to remember that even though you start on two or three drugs, or even you start on one drug, you need to follow the patient to see what happens. If you get a gratifying response, great. But if you dont, then you need to move on quickly, either adding one or two additional drugs.

Steve Freed:Now, you had mentioned, if you go back 50 years, we had one oral drug. Today, we have a couple million possible combinations if you include insulin in there. What you see coming down the pike as far as the future because it used to be simple. You go to your doctor, and he gives you a prescription for sulfonylurea. Today, theres so many options and so many new drugs that each of them has side effects. Theyre all a little bit different. Theyre certainly better than what we had. How do you teach a physician, what possible combination he should use? Is it just trial-and-error?

Dr. Defronzo:Well, I think for endocrinologists, its a little bit easier because this is our job. I think the real problem is amongst primary care physicians because they have to learn all of these new diabetes drugs. Then they have G.I. problems. They have to learn all of these new G.I. drugs. Then they have people presenting with arthritis and collagen vascular disease. Then we have this whole new plethora of immuno-suppressive drugs. I feel sorry in a certain way for the primary care physician because hes supposed to be an expert in everything. Well, thats not possible. The good part is we have very good medications. So thats an advantage. Sometimes I see patients coming to me, I wonder why are they on these drugs when theyre not well controlled, when there are better drugs. It sounds easy for us. I see a patient literally in 10 to 15 minutes, I can handle all the problems. I know instantaneously what to do with glucose, lipids, blood pressure, and cardiovascular issues. Thats basically the major part of diabetes cardiovascular hypertension treatment. And since Im board certified in nephrology as well, I know if they get kidney problems what to do. So for me its very easy to take care of diabetic patients. Its not so easy for primary care physicians and then on top of all of that, we have cost. These newer drugs are really quite expensive. Also, if you prescribe a drug thats not on the patients formulary and he goes to pick it up and its $500, believe me you havent prescribed any drug, because hes not going to get it. Even though, the docs may understand what drugs do and what are the good ones, not always can you prescribe them for your patients.

Return to main page.

Visit link:
Dr. Ralph Defronzo Part 3, Diabetes Medications - Diabetes In Control

Posted in Diabetes | Comments Off on Dr. Ralph Defronzo Part 3, Diabetes Medications – Diabetes In Control

Diabetes-Prevention Camp To Be Held In Santa Clarita … – KHTS Radio

Posted: June 24, 2017 at 1:43 pm

American Diabetes Association officials are offering a summer diabetes-prevention camp in Santa Clarita from July 1516, 2017, from 9 a.m. to 4 p.m. at the Boys & Girls Club of Santa Clarita.

This camp is available for 7- to 15-year-olds who are at risk for diabetes or that have a family history of Type 2 diabetes.

To register, visit the Camp Power Up website at http://www.diabetes.org/camppowerupsantaclarita or call 323-966-2890.

Obesity continues to pose a threat to the health of Americans, as Type 2 diabetics make up 90-95 percent of all diabetics in the world.

Approximately 208,000 Americans under age 20 are estimated to have diagnosed diabetes, according to the American Diabetes Association.

In order to combat this statistic, create new habits and become knowledgeable about Type 2 diabetes prevention, the diabetes camp will focus on exercise, proper nutrition and fellowship between children in similar health circumstances.

Parents and other family members are encouraged to attend camp on Sunday in order to reinforce the healthy lifestyle their children learned about on Saturday.

In addition to the weekend long camp experience, all children and their families are invited to attend three Reunion Events hosted at the Boys & Girls Club in Newhall.

Risk factors for Type 2 diabetes are being overweight, sedentary, and having a family history of diabetes. African Americans, Hispanics/Latinos, Native Americans, Asian Americans and Pacific Islanders are at an increased risk for developing the disease.

However, Type 2 diabetes can be reversed via exercise, nutrition, and a change in lifestyle choices.

About the American Diabetes Association

The American Diabetes Association is leading the fight to Stop Diabetes and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. For the past 75 years, our mission has been to prevent and cure diabetes and to improve the lives of all people affected by diabetes. For more information please call the American Diabetes Association at 1-800-DIABETES (800-342-2383) or the Los Angeles office at 323.966.2890 or visit http://www.diabetes.org Find the Los Angeles office on Facebook (adalosangeles), Twitter (@ada_losangeles) and Instagram (@adalosangeles).

See the original post here:
Diabetes-Prevention Camp To Be Held In Santa Clarita ... - KHTS Radio

Posted in Diabetes | Comments Off on Diabetes-Prevention Camp To Be Held In Santa Clarita … – KHTS Radio

Page 1,528«..1020..1,5271,5281,5291,530..1,5401,550..»